Dose-dependent severe cutaneous reactions to imatinib

The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugurel, S, Hildenbrand, R, Dippel, E, Hochhaus, A, Schadendorf, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747559/
https://www.ncbi.nlm.nih.gov/pubmed/12698177
http://dx.doi.org/10.1038/sj.bjc.6600893
_version_ 1782172108460130304
author Ugurel, S
Hildenbrand, R
Dippel, E
Hochhaus, A
Schadendorf, D
author_facet Ugurel, S
Hildenbrand, R
Dippel, E
Hochhaus, A
Schadendorf, D
author_sort Ugurel, S
collection PubMed
description The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.
format Text
id pubmed-2747559
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27475592009-09-21 Dose-dependent severe cutaneous reactions to imatinib Ugurel, S Hildenbrand, R Dippel, E Hochhaus, A Schadendorf, D Br J Cancer Clinical The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity. Nature Publishing Group 2003-04-22 2003-04-15 /pmc/articles/PMC2747559/ /pubmed/12698177 http://dx.doi.org/10.1038/sj.bjc.6600893 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Ugurel, S
Hildenbrand, R
Dippel, E
Hochhaus, A
Schadendorf, D
Dose-dependent severe cutaneous reactions to imatinib
title Dose-dependent severe cutaneous reactions to imatinib
title_full Dose-dependent severe cutaneous reactions to imatinib
title_fullStr Dose-dependent severe cutaneous reactions to imatinib
title_full_unstemmed Dose-dependent severe cutaneous reactions to imatinib
title_short Dose-dependent severe cutaneous reactions to imatinib
title_sort dose-dependent severe cutaneous reactions to imatinib
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747559/
https://www.ncbi.nlm.nih.gov/pubmed/12698177
http://dx.doi.org/10.1038/sj.bjc.6600893
work_keys_str_mv AT ugurels dosedependentseverecutaneousreactionstoimatinib
AT hildenbrandr dosedependentseverecutaneousreactionstoimatinib
AT dippele dosedependentseverecutaneousreactionstoimatinib
AT hochhausa dosedependentseverecutaneousreactionstoimatinib
AT schadendorfd dosedependentseverecutaneousreactionstoimatinib

Ejemplares similares